|By PR Newswire||
|February 13, 2014 10:34 AM EST||
NEW YORK, Feb. 13, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Diabetes – KOL Insight and Consensus Outlook Modules
The medium term: battle lines are drawn
The fundamental drivers of the global diabetes market are strong and continue to fuel growth. Rising levels of obesity and disease prevalence in both established and emerging markets have seen the sector return a 5 year compound annual growth rate (CAGR) of 12% over to reach US$31.9 billion in 2012. It is estimated that 347 million people have the disease – 90% of whom are Type II diabetes sufferers – and this figure could almost double by 2030.
The big four companies in diabetes - Novo Nordisk, Sanofi, Eli Lilly and Merck – are locked in a battle of supremacy which is set to continue over the medium term. While Novo Nordisk currently leads the pack, Sanofi is close behind. With Novo Nordisk's approval of Tresiba (insulin degedec) stalled in the US over safety concerns, Sanofi latest version of Lantus U300 (insulin glargine)) could capitalise. Bristol Myers-Squibb and AstraZeneca are just two of the other players set to increase their sales significantly in this busy market place by 2017.
The diabetes market will continue on an upward trajectory, and an estimated 5 year CAGR of 11 percent will see the sector top US$54 billion – the question is which companies will have a slice to this market, and how big will it be?
What's in the pipeline?
Finding market voice for new products in diabetes depends critically on price and differentiation. Cost of treatment is already an issue and resistance can be expected from health payers if new products offer only marginal therapeutic or patient management benefits. For example, excitement about Sanofi's U300 (insulin glargine) is because it shows differentiation to Lantus with "peakless" delivery and longer duration. Eli Lilly's weekly dose dulaglutide may offer advantages over other launched and pipeline GLP-1 products such as such as GSK's Eperzan (albiglutide) and BMS/AZ/Amylin's Bydureon (exanatide) but meaningful advantages need to be shown for success in the market.
What the Future Holds: is there a Game Changer on the Horizon?
Don't expect a revolution in diabetes treatment soon. New products coming to market are essentially incremental improvements over current approaches, with better safety profiles and geared to improving patient compliance.
The real prize will be for the company that can bring a paradigm shift to the treatment of diabetes. Upsetting the status quo will require a fundamentally different approach - and some of these developments threaten the diabetes drugs manufacturers existing revenues.
Among the developments to be aware of are the threat of biosimilars, the development of an artificial pancreas 'closed loop' system, the wide implementation of which would be a doomsday development for drugs companies, and a DNA reverse vaccine for which early clinical results have shown promising results.
A Complete Ongoing Analysis of Current Trends, Future Forecasts and Landscape Modifiers
For instant access to an accurate, unbiased, qualitative review of the latest treatment trends along with a five-year quantitative diabetes market forecast look no further than FirstWord's Therapy Trends: Diabetes. This comprehensive FirstWord research is available in two comprehensive modules:
• The KOL Insight: Diabetes module provides a complete review and is enhanced with exclusive in-depth interviews with leading KOLs from the US and Europe
• TThe Consensus Outlook: Diabetes data analysis module provides annual historical and forecast product-level sales data from an average of leading equity analysts' projections
Therapy Trends KOL Insight: Diabetes analyses the current and predicted key issues, current products and late-stage pipeline products. The report gives you qualitative, inside information from exclusive FirstWord interviews with 12 key opinion leaders (KOLs) through the following:
• KOL Insight Report — an in-depth analytical report on diabetes treatment trends
• Full report updates — issued to you after each and every significant diabetes market event
• Event Bulletins — the latest KOL views in response to each event
Key Report Features and Benefits
• Critical insights on products and market developments from leading US and European clinicians
• Complete coverage of all sub sectors - Basal, Prandial and Premixed insulins, DPP-IV inhibitors, GLP-1 agonists/analogues, SGLT-2 inhibitors, Thiazolidinediones and other non insulin anti diabetics
• Assessment of current leading diabetes products by sub sector
• Analysis of late-stage pipeline diabetes therapies by sub sector
• Competitive evaluation of leading players
• Current thinking and trends in the treatment of diabetes
• Predicted KOL treatment trends and market leaders
• Ongoing FirstWord clinical and market updates
Expert Opinion for Real World Insights
The data and analysis in the report is enriched through the specific insights and opinions of leading clinicians working in diabetes in the US and Europe. Their views on specific drugs and treatment pathways provide a unique front line perspective from those working in clinical setting. The results of these detailed and extensive interviews are incorporated though out the text so they can be read in the context of the issue or product being discussed.
• Dr Elif Oral, MD, Associate Professor of Endocrinology, University of Michigan, Ann Arbor, MI.
• Dr Sonal Singh, MD, MPH, Assistant Professor, Division of General Internal Medicines, John Hopkins University, Baltimore, MD.
• Dr Carol Wysham, MD, Clinical Associate Professor of Medicine, Division of General Internal Medicines, University of Washington School of Medicine, Washington.
• Dr Joel Zonszein, MD, Director of the Clinical Diabetes Center at the University Hospital Albert Einstein College of Medicine, a Division of Montefiori Medical Center, NY.
• Requested anonymous, Associate Professor of Medicine, Endocrinology and Metabolism, Duke University, Durham, NC.
• Professor Bernard Charbonnel, MD, Professor of Endocrinology and Metabolic Diseases, University of Nantes; Head of the Internal Medicine, Endocrinology and Diabetes Department, Hôtel Dieu, University Hospital of Nantes, France.
• Professor Melanie Davies, MD, Honorary Consultant, Diabetes, University Hospital Leicester, Leicestershire, UK.
• Professor Marc Donath, MD, Director, Endocrinology, Diabetes and Clinical Nutrition, University Hospital, Basel, Switzerland.
• Professor Baptist Gallwitz, MD, Professor, Professor of Medicine, Diabetes, Eberhard Karls University, University Hospital of Tuebingen, Germany.
• Professor Jens Holst, MD, Professor of Medical Physiology, Department of Biomedical Sciences; Director of the Research Cluster for Diabetes and Obesity; Vice Chairman, Faculty of Health Sciences, University of Copenhagen, Denmark.
• Professor Michael Nauck, MD, Head, Diabeteszentrum Bad Lauterberg, Harz, Germany.
• Professor John Wilding, MD, Head of the Department of Obesity and Endocrinology, University of Liverpool, UK.
Key Quotes from the Report
"I like Janumet. I get a much more effective medication even in one pill a day using combination therapy. Janumet has this long acting glycol, so it is long acting. In early diabetes, together with lifestyle changes, I often use a combination of DPP-IV with metformin, either once or twice a day because it doesn't cause hypoglycaemia. The patients don't need to monitor their blood sugar three, four, five times a day. They don't get admitted to the hospital with hypoglycaemia so the side effects are low. So I start treating these patients with a combination therapy, like Janumet." Dr Joel Zonszein (US)
"I think lots of people use Kombiglyze because it improves compliance so it makes sense. In the therapeutic armamentarium it's the only real once daily combination." Professor Sonal Singh (US)
"In terms of efficacy, side effects, convenience and device, Victoza is the preferred GLP-1. If I look at the new-starts, probably 60 percent of people are going for the Victoza" Dr Carol Wysham (US)
"The prevention of hypoglycaemia is a very important aim for the classical drugs and an unmet need. We should be searching for alternatives to insulin." Professor Baptist Gallwitz (EU)
"I am not too optimistic that you can improve DPP-IV inhibitors to be more efficacious. You may well be able to improve GLP-1 agonists to have more efficacious drugs that have less side effects based on the variety within the class that we have seen until now. I think that the pharmaceutical industry as a whole is a little bit running out of ideas, so we really need to identify good targets." Professor Michael Nauck (EU)
"I think if someone came up with a reasonably well-tolerated drug that helped you lose weight [and] that you only had to take once a month or once a year? Everyone would be on that. US Key Opinion Leader
"Our local insurance company have taken all of what they consider tier 3 drugs, and they include all the GLP-1 agents including the DPP-IV inhibitors, and just put them on a 50-percent co-pay. Fifty percent of a lot of money is still a lot of money." Dr Carol Wysham (US)
KOL Insights -- Key Topics
• Current diabetes marketplace
• Current treatment landscape
• Reimbursement of key diabetes brands
• Current marketed therapies
• Pipeline therapies
• Unmet needs
• Current treatment algorithm
• Future treatment algorithm
• Future developments in Diabetes
Use this detailed report and powerful interactive Excel spreadsheet to compare and contrast companies and products now and in the future. Therapy Trends Consensus Outlook: Diabetes includes the following comprehensive resources:
• An in-depth forecast report based on consensus figures from 13 leading analysts. Rich in tables and charts, the report maps the impact of future events to predict product and company performance
• An interactive forecast data analysis spreadsheet comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017
• Timely event-driven market forecast report and data analysis updates over 12 months
• Historical diabetes sales from 2007–2012
• Forecast diabetes sales from 2013-2017
• Key competitors and drug developers
• Current and late-stage pipeline drugs
• Future event mapping to forecast data points
• Expected impacting factors on global forecasts
Use Consensus Outlook to:
• •Chart predicted market growth and product sales
• Map your own market parameters
• Tailor your strategic and investment focus
• Assess your current and future sales resources
• Set proactive launches and branding strategies
• Barclays Capital
• Credit Suisse
• Deutsche Bank
• Goldman & Sachs
• International Strategy & Investment
• JP Morgan
• Merrill Lynch
• Morgan & Stanley
• Societe Generale
• Stifel Nicolaus
Content Highlights and Products Covered:
• Research Methodology
• Diabetes Marketplace
• Key Diabetes Developers
• Diabetes Class Dynamics
• Lantus (insulin glargine; Sanofi) forecast
• Levemir (insulin detemir; Novo Nordisk) forecast
• Tresiba (insulin degludec; Novo Nordisk) forecast
• Ryzodeg (degludecPlus; Novo Nordisk) forecast
• NovoRapid/NovoLog (insulin aspart; Novo Nordisk) forecast
• Humalog (insulin lispro; Eli Lilly) forecast
• Apidra (insulin glulisine; Sanofi) forecast
• NovoMix/NovoLog Mix (insulin aspart + insulin aspart protamine; Novo Nordisk) forecast
• Januvia franchise (sitagliptin; Merck & Co) forecast
• Galvus franchise (vildagliptin; Novartis) forecast
• Onglyza franchise (saxagliptin; Bristol-Myers Squibb/AstraZeneca/ Otsuka) forecast
• Nesina franchise (alogliptin; Takeda) forecast
• Tradjenta franchise (linagliptin; Boehringer Ingelheim/Eli Lilly) forecast
• Byetta (exenatide; Bristol-Myers Squibb/AstraZeneca/Amylin) forecast
• Bydureon (exenatide once-weekly; Bristol-Myers Squibb/AstraZeneca/ Amylin) forecast
• Victoza (liraglutide; Novo Nordisk) forecast
• Lyxumia (lixisenatide; Sanofi) forecast
• Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe) forecast
• Forxiga (dapagliflozin; Bristol-Myers Squibb/AstraZeneca) forecast
• Actos (pioglitazone; Takeda) forecast
• U300 (insulin glargine; Sanofi) forecast
• LY2605541 (insulin peglispro; Eli Lilly) forecast
• LY2963016 (biosimilar insulin glargine; Eli Lilly/Boehringer Ingelheim) forecast
• IDeglira (liraglutide + insulin degludec; Novo Nordisk) forecast
• Afrezza (Technosphere Insulin; MannKind Corporation) forecast
• FIAsp (insulin aspart; Novo Nordisk) forecast
• Eperzan (albiglutide; GlaxoSmithKline/Human Genome Sciences) forecast
• LY2189265 (dulaglutide; Eli Lilly) forecast
• BI-10773 (empagliflozin; Boehringer Ingelheim/Eli Lilly) forecast
Contents Consensus Outlook
1.FirstWord Analysis Highlights
4.Key Diabetes Developers
5.Diabetes Class Dynamics
6.Lantus (insulin glargine; Sanofi) forecast
7.Levemir (insulin detemir; Novo Nordisk) forecast
8.Tresiba (insulin degludec; Novo Nordisk) forecast
9.Ryzodeg (degludecPlus; Novo Nordisk) forecast
10.NovoRapid/NovoLog (insulin aspart; Novo Nordisk) forecast
11.Humalog (insulin lispro; Eli Lilly) forecast
12.Apidra (insulin glulisine; Sanofi) forecast
13.NovoMix/NovoLog Mix (insulin aspart + insulin aspart protamine; Novo Nordisk) forecast
14.Januvia franchise (sitagliptin; Merck & Co) forecast
15.Galvus franchise (vildagliptin; Novartis) forecast
16.Onglyza franchise (saxagliptin; Bristol-Myers Squibb/AstraZeneca/ Otsuka) forecast
17.Nesina franchise (alogliptin; Takeda) forecast
18.Tradjenta franchise (linagliptin; Boehringer Ingelheim/Eli Lilly) forecast
19.Byetta (exenatide; Bristol-Myers Squibb/AstraZeneca/Amylin) forecast
20.Bydureon (exenatide once-weekly; Bristol-Myers Squibb/AstraZeneca/ Amylin) forecast
21.Victoza (liraglutide; Novo Nordisk) forecast
22.Lyxumia (lixisenatide; Sanofi) forecast
23.Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe) forecast
24.Forxiga (dapagliflozin; Bristol-Myers Squibb/AstraZeneca) forecast
25.Actos (pioglitazone; Takeda) forecast
26.U300 (insulin glargine; Sanofi) forecast
27.LY2605541 (insulin peglispro; Eli Lilly) forecast
28.LY2963016 (biosimilar insulin glargine; Eli Lilly/Boehringer Ingelheim) forecast
29.IDeglira (liraglutide + insulin degludec; Novo Nordisk) forecast
30.Afrezza (Technosphere Insulin; MannKind Corporation) forecast
31.FIAsp (insulin aspart; Novo Nordisk) forecast
32.Eperzan (albiglutide; GlaxoSmithKline/Human Genome Sciences) forecast
33.LY2189265 (dulaglutide; Eli Lilly) forecast
34.BI-10773 (empagliflozin; Boehringer Ingelheim/Eli Lilly) forecast
4.Current diabetes marketplace
5.7.Complications of diabetes
5.10.Current treatment landscape
5.11.Reimbursement of key diabetes brands
6.Current marketed therapies
6.4.Dipeptidyl Peptidase-IV (DPP-IV) inhibitors
6.5.Glucagon-like peptide-1 (GLP-1) agonists/analogues
6.6.Sodium-glucose co-transporter-2 (SGLT-2) inhibitors
6.8.Other non-insulin anti-diabetics
7.1.Pipeline basal insulins
7.2.Pipeline prandial insulins
7.3.Pipeline dipeptidyl peptidase-IV (DPP-IV) inhibitors
7.4.Pipeline glucagon-like peptide-1 (GLP-1) agonists/analogues
7.5.Pipeline sodium-glucose co-transporter 2 (SGLT-2) inhibitors
7.6.Other pipeline non-insulin anti-diabetics
8.1.Unmet needs in type 1 diabetes
8.2.Unmet needs in type 2 diabetes
8.3.Current treatment algorithm- Type2 diabetes
8.4.Future treatment algorithm
9.Future developments in Diabetes
9.1.Biosimilar insulin commercial threat limited
9.2.Continuous glucose monitoring and closed loop systems
9.3.Transplantation or regeneration of beta-cells
9.4.Targeting immune response and inflammation
To order this report: Diabetes – KOL Insight and Consensus Outlook Modules
Contact Clare: [email protected]
Intl: +1 339-368-6001
"Qosmos has launched L7Viewer, a network traffic analysis tool, so it analyzes all the traffic between the virtual machine and the data center and the virtual machine and the external world," stated Sebastien Synold, Product Line Manager at Qosmos, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 3, 2016 07:00 AM EST Reads: 452
In addition to all the benefits, IoT is also bringing new kind of customer experience challenges - cars that unlock themselves, thermostats turning houses into saunas and baby video monitors broadcasting over the internet. This list can only increase because while IoT services should be intuitive and simple to use, the delivery ecosystem is a myriad of potential problems as IoT explodes complexity. So finding a performance issue is like finding the proverbial needle in the haystack.
Dec. 3, 2016 06:30 AM EST Reads: 5,975
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life sett...
Dec. 3, 2016 05:45 AM EST Reads: 6,906
The WebRTC Summit New York, to be held June 6-8, 2017, at the Javits Center in New York City, NY, announces that its Call for Papers is now open. Topics include all aspects of improving IT delivery by eliminating waste through automated business models leveraging cloud technologies. WebRTC Summit is co-located with 20th International Cloud Expo and @ThingsExpo. WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web ...
Dec. 3, 2016 05:30 AM EST Reads: 1,195
Redis is not only the fastest database, but it has become the most popular among the new wave of applications running in containers. Redis speeds up just about every data interaction between your users or operational systems. In his session at 18th Cloud Expo, Dave Nielsen, Developer Relations at Redis Labs, shared the functions and data structures used to solve everyday use cases that are driving Redis' popularity.
Dec. 3, 2016 04:15 AM EST Reads: 3,415
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
Dec. 3, 2016 04:15 AM EST Reads: 1,707
Internet-of-Things discussions can end up either going down the consumer gadget rabbit hole or focused on the sort of data logging that industrial manufacturers have been doing forever. However, in fact, companies today are already using IoT data both to optimize their operational technology and to improve the experience of customer interactions in novel ways. In his session at @ThingsExpo, Gordon Haff, Red Hat Technology Evangelist, will share examples from a wide range of industries – includin...
Dec. 3, 2016 02:30 AM EST Reads: 1,519
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
Dec. 3, 2016 02:15 AM EST Reads: 1,489
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Phil Hombledal, Solution Architect at CollabNet, discussed how customers are able to achieve a level of transparency that e...
Dec. 3, 2016 02:15 AM EST Reads: 736
Much of the value of DevOps comes from a (renewed) focus on measurement, sharing, and continuous feedback loops. In increasingly complex DevOps workflows and environments, and especially in larger, regulated, or more crystallized organizations, these core concepts become even more critical. In his session at @DevOpsSummit at 18th Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, showed how, by focusing on 'metrics that matter,' you can provide objective, transparent, and meaningful f...
Dec. 3, 2016 01:45 AM EST Reads: 4,532
"We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 3, 2016 01:45 AM EST Reads: 766
"We are the public cloud providers. We are currently providing 50% of the resources they need for doing e-commerce business in China and we are hosting about 60% of mobile gaming in China," explained Yi Zheng, CPO and VP of Engineering at CDS Global Cloud, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 3, 2016 01:15 AM EST Reads: 854
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at 20th Cloud Expo, Ed Featherston, director/senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Dec. 3, 2016 12:30 AM EST Reads: 1,519
Between 2005 and 2020, data volumes will grow by a factor of 300 – enough data to stack CDs from the earth to the moon 162 times. This has come to be known as the ‘big data’ phenomenon. Unfortunately, traditional approaches to handling, storing and analyzing data aren’t adequate at this scale: they’re too costly, slow and physically cumbersome to keep up. Fortunately, in response a new breed of technology has emerged that is cheaper, faster and more scalable. Yet, in meeting these new needs they...
Dec. 3, 2016 12:15 AM EST Reads: 1,752
"Once customers get a year into their IoT deployments, they start to realize that they may have been shortsighted in the ways they built out their deployment and the key thing I see a lot of people looking at is - how can I take equipment data, pull it back in an IoT solution and show it in a dashboard," stated Dave McCarthy, Director of Products at Bsquare Corporation, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 2, 2016 11:15 PM EST Reads: 904